Regeneron Pharmaceuticals Stock News

Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) earned $23.72 per share for Q4 FY21 , more than double from $9.53 a year ago, beating the $18.11 estimate. Q4 sales almost doubled to $4.95 billion from $2.42 billion, surpassing the analysts'' consensus of $4.47 billion, fueled by sales of COVID-19 treatment, REGEN-COV. Excluding REGEN-COV sales of $2.29 billion, sales increased 17% Full story available on Benzinga.com

Regeneron Pharmaceuticals, Inc. (REGN) CEO Dr. Len Schleifer on Q4 2021 Results - Earnings Call Transcript

Regeneron Pharmaceuticals press release (REGN): Q4 Non-GAAP EPS of $23.72 beats by $3.67.Revenue of $4.95B (+104.5% Y/Y) beats by $460M. REGEN-COV®(2); revenues

Regeneron Pharma Earnings, Revenue Beat in Q4

The FDA recently revoked Emergency Use Authorization of their COVID-19 treatments.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 1.9% to trade at $632.42 at last check, after the drug maker posted a top- and bottom-line beat for its fourth quarter, which included revenues nearl

Regeneron (REGN) delivered earnings and revenue surprises of 28.29% and 7.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Regeneron Pharmaceuticals Inc  REGN earned $23.72 per share for Q4 FY21, more than double from $9.53 a year ago, beating the $18.11 estimate.  Get the Inside Access Traders Are Using to Profit More

Regeneron Pharmaceuticals Inc. shares REGN, -0.35% rose 1.8% in premarket trade Friday, after the company doubled its fourth-quarter revenue as sales of its COVID-19 antibody treatment came to $2.3 bi

Regeneron Pharmaceuticals quarterly profit nearly doubled on Thursday, on strong sales of its COVID-19 antibody cocktail.

Regeneron Pharmaceuticals (REGN) is scheduled to announce Q4 earnings results on Friday, February 4, 2022, before the market opens.The consensus EPS estimate is $19.41 (+103.67% Y/Y)…

Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

As of Jan. 31, the following stocks look underestimated by the market, as their price-earnings ratios without non-recurring items trade below 20 while their price-earnings to growth (PEG) ratios trade

After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. About 3 new molecular entities, or NMEs, were approved during the month, including Immunocore Holdings plc''s (NASDAQ: IMCR ) Kimmtrak for certain patients with advanced eye melanoma and Pfizer, Inc.''s (NYSE: PFE ) atopic dermatitis treatment Cibinqo. NME approval is an important indicator to measure innovation in drug research. NME approvals totaled 50 in 2021, almost equaling the numbers of the previous year. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN )- Sanofi (NASDAQ: SNY ), however, failed to get the nod for expanding the Libtayo label to include cervical cancer. Pfizer also faced rejection for its pediatric growth hormone deficiency treatment Somatrogon. A PDUFA date is the date/period by which the Food and Drug Administration is required to announce its verdict on a sponsor company''s regulatory application. This will determine the fate of millions of dollars invested in developing the treatment from the preclinical-stage to clinical testing.

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVA